Literature DB >> 28894848

Risk Reduction Strategies in Breast Cancer Prevention.

Mauricio Costa1, Paula Saldanha1.   

Abstract

Evaluating the risk of breast cancer makes it possible to identify women with a high risk of developing breast cancer in the future. Adopting a healthier lifestyle, involving diet and exercise, is one way of reducing this risk-but there are other, non-modifiable risk factors, such as family history, genetics and diagnosis of premalignant lesions. In this high-risk population, the tracking must be rigorous and involve the participation of the patient herself, earlier and more frequent clinical assessment, and the use of imaging screening. Agents such as tamoxifen, raloxifene and aromatase inhibitors may be used in chemoprevention and may reduce the risk substantially. The risks and benefits must be assessed, and one must discuss with the patient her adverse events and the decision regarding the best treatment. Women who carry the BRCA1/2 mutation (very high risk) can benefit from prophylactic surgical interventions, such as bilateral mastectomy and/or bilateral salpingo-oophorectomy. This group of patients must be monitored by a multidisciplinary team, providing explanations prior to surgery regarding the surgical treatment offered, the reconstruction techniques, and the risks and complications.

Entities:  

Keywords:  Breast; mastectomy; risk; serm oophorectomy

Year:  2017        PMID: 28894848      PMCID: PMC5544140          DOI: 10.5152/ejbh.2017.3583

Source DB:  PubMed          Journal:  Eur J Breast Health


  39 in total

1.  Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study.

Authors:  Bertrand Tehard; Christine M Friedenreich; Jean-Michel Oppert; Francoise Clavel-Chapelon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-01       Impact factor: 4.254

Review 2.  The role of the fallopian tube in the origin of ovarian cancer.

Authors:  Britt K Erickson; Michael G Conner; Charles N Landen
Journal:  Am J Obstet Gynecol       Date:  2013-04-10       Impact factor: 8.661

3.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

4.  Selective use of sentinel lymph node surgery during prophylactic mastectomy.

Authors:  Judy C Boughey; Nazanin Khakpour; Funda Meric-Bernstam; Merrick I Ross; Henry M Kuerer; Sonja E Singletary; Gildy V Babiera; Banu Arun; Kelly K Hunt; Isabelle Bedrosian
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

5.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Authors:  Trevor J Powles; Sue Ashley; Alwynne Tidy; Ian E Smith; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

6.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

7.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Authors:  Silvana Martino; Jane A Cauley; Elizabeth Barrett-Connor; Trevor J Powles; John Mershon; Damon Disch; Roberta J Secrest; Steven R Cummings
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

8.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  Osteoporosis after oophorectomy for non-malignant disease in premenopausal women.

Authors:  J M Aitken; D M Hart; J B Anderson; R Lindsay; D A Smith; C F Speirs
Journal:  Br Med J       Date:  1973-05-12

Review 10.  Breast cancer risk-assessment models.

Authors:  D Gareth R Evans; Anthony Howell
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  5 in total

1.  Decorated Superparamagnetic Iron Oxide Nanoparticles with Monoclonal Antibody and Diethylene-Triamine-Pentaacetic Acid Labeled with Thechnetium-99m and Galium-68 for Breast Cancer Imaging.

Authors:  Marta de Souza Albernaz; Sergio Hiroshi Toma; Jeff Clanton; Koiti Araki; Ralph Santos-Oliveira
Journal:  Pharm Res       Date:  2018-01-05       Impact factor: 4.200

2.  Economic evaluations of mammography to screen for breast cancer in low- and middle-income countries: A systematic review.

Authors:  Ajeng V Icanervilia; Jurjen van der Schans; Qi Cao; Adriana C de Carvalho; Kathya Cordova-Pozo; Jarir At Thobari; Maarten J Postma; Antoinette DI van Asselt
Journal:  J Glob Health       Date:  2022-07-16       Impact factor: 7.664

3.  Apps for individuals diagnosed with breast cancer: a preliminary assessment of the content and quality of commercially available apps in Spanish.

Authors:  Rubén Martín-Payo; Llara Ferreras-Losilla; Xana González-Méndez; Claudia Leirós-Díaz; Andrea Martínez-Urquijo; Maria Del Mar Fernández-Álvarez
Journal:  Mhealth       Date:  2021-01-20

Review 4.  Overview of the genetic basis toward early detection of breast cancer.

Authors:  Sumadee De Silva; Kamani Hemamala Tennekoon; Eric Hamilton Karunanayake
Journal:  Breast Cancer (Dove Med Press)       Date:  2019-01-21

Review 5.  Melatonin: A Molecule for Reducing Breast Cancer Risk.

Authors:  Alicia González-González; María Dolores Mediavilla; Emilio J Sánchez-Barceló
Journal:  Molecules       Date:  2018-02-06       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.